Experiences of a Bioinformatics Company in. Dr Othmar Pfannes 4 November 2016 Basel

Size: px
Start display at page:

Download "Experiences of a Bioinformatics Company in. Dr Othmar Pfannes 4 November 2016 Basel"

Transcription

1 Experiences of a Bioinformatics Company in Dr Othmar Pfannes 4 November 2016 Basel

2 Agenda About Genedata Genedata in Japan Q&A 2

3 Genedata Snapshot Roots Established in 1997 Privately owned Headquartered in Switzerland Global Reach ~ 200 employees Offices in Europe (Basel, Munich), North America (Boston, San Francisco) & Asia (Tokyo) Innovative Leader enterprise software systems for genedata related research & development Unique Domain Expertise Experienced Ph.D. level experts coupled with efficient software engineering processes Marquee Customer Base Leading pharmaceutical, biotechnology, and other life science organizations 3

4 Marquee Customer Base 25 of Top 25 BioPharma 5 of Top 5 Agri Biotechs Leading Industrial Biotechs San Francisco Boston Basel Munich Tokyo 2016 Genedata CONFIDENTIAL 4

5 Solutions from Discovery to Manufacturing Biologics Large-molecule discovery Bioprocess Large-molecule development Expressionist Analytical characterization Imagence Image-based research Profiler Patient characterization Screener Molecular identification Selector Cell line optimization Target Discovery Lead Discovery Translational Research Pre-clinical Development Clinical Development Manufacture 5

6 Our Business Model Analytical Workflow Systems Enterprise, modular, turn-key Domain Expertise unique mix of science, IT & business know-how Top50 Pharma, Biopharma, Industrial & Agro Biotech Creating Efficiencies automating complex R&D workflows Enabling Innovation providing scalable data analytics Selling Software Licenses & Consulting 2016 Genedata CONFIDENTIAL 6

7 Why Japan? Global Ranking Top 10 Japanese Pharma Companies Rev 2015 [in Mio $] 17 Takeda 13, Astellas 11, Daiichi Sankyo 8, Otsuka HD 7, Eisai 4, Chugai 4, Mitsubishi Tanabe 3, Sumitomo Dainippon 2, Shionogi 2, Kyowa Hakko Kirin 2,317 7

8 Genedata s success in Japan: 7 out of Top10 (plus 2) Global Ranking Top 10 Japanese Pharma Companies Rev 2015 [in Mio $] 17 Takeda (2009) 13, Astellas (2008) 11, Daiichi Sankyo (2009) 8, Otsuka HD 7, Eisai (2011) 4, Chugai (2007) 4, Mitsubishi Tanabe (2015) 3, Sumitomo Dainippon 2, Shionogi (2013) 2, Kyowa Hakko Kirin 2,317 Taisho (2014) Ono (2011) 8

9 Genedata Japanese History Early Successes in Europe Global Expansion to US & JP 2001 Started with Japanese Distributor in JP not successful 2005 Founded Genedata KK with office in Tokyo & 2 employees 2011 Break-even 2016 Profitable Growing Business 10 FTEs Only 2 of 7 solutions currently offered in Japan 9

10 KK revenue Exchange Rate Forecasts Y 2007 Y 2008 Y 2009 Y 2010 Y 2011 Y 2012 Y 2013 Y 2014 Y 2015 Y 2016 Y

11 Why are we successful in Japan? High quality of Genedata solutions Unique end-to-end enterprise product Continuous high-quality support from Basel Flexibility in price Understanding Japanese business culture & market situation Realistic growth expectations 11

12 Some Observations Japanese customers require high quality product very demanding wrt support committed if you deliver on promises Doing business in Japan structured & well organized predictable & transparent Japanese Personnel high scientific quality eager to learn hard working committed English language skills are big problem Managing Director with great business skills key for success 12

13 Where do we go from here in Japan? Continue with natural growth path Grow when Japanese market is ready Currently introducing 3 rd product to Japanese market Plan to hire ~ 1 FTE/year Scientific domain expertise, business understanding & communication skills Invest significantly in training Try closing deals at higher decision level Increased deal sizes Genedata solutions become part of infrastructure Building trust level at senior management Expansion to new markets beyond pharma Agri-Business? Industrial Biotech? Consumer Goods? 13

14 ご清聴有難う御座いました 14

World s Leading Pharmaceutical R&D and Manufacturing Trade Show

World s Leading Pharmaceutical R&D and Manufacturing Trade Show World s Leading Pharmaceutical R&D and Manufacturing Trade Show Dates: June 29(Wed)-July 1(Fri), 2016Venue: Tokyo Big Sight, Japan Organised by : Reed Exhibitions Japan Ltd. Concurrent Shows: in-pharma

More information

Exhibition & Conference

Exhibition & Conference Exhibiting Information Asia s Leading Bio Event Exhibition, Partnering & Conference 7th Int l Biotech & Life Sciences Exhibition & Conference Dates: June 27(Wed) 29(Fri), 208 Venue: Tokyo Big Sight, Japan

More information

Index Day reports (ADR)...59, 125

Index Day reports (ADR)...59, 125 Index 15-Day reports (ADR)...59, 125 30-Day reports (ADR)...126 7-Day reports (ADR)...59 ADR reporting system Reporting by pharmaceutical companies...125 ADR Reporting System Reporting by MHLW...124 Advanced

More information

Asia s Premier Partnering Event for the Biotechnology Industry. Makoto TANIHARA ICS Convention Design, Inc.

Asia s Premier Partnering Event for the Biotechnology Industry. Makoto TANIHARA ICS Convention Design, Inc. Asia s Premier Partnering Event for the Biotechnology Industry Makoto TANIHARA ICS Convention Design, Inc. February 2013 0 Overview Event Outline BioJapan 2013 -World Business Forum- Date: October 9 (Wed.)-

More information

2010/SOM3/LSIF/002. Opening Remarks. Submitted by: Japan Pharmaceutical Manufacturers Association (JPMA)

2010/SOM3/LSIF/002. Opening Remarks. Submitted by: Japan Pharmaceutical Manufacturers Association (JPMA) 010/SOM/LSIF/00 Opening Remarks Submitted by: Japan Pharmaceutical Manufacturers Association (JPMA) Life Sciences Innovation Forum Sendai, Japan 18-19 September 010 Message From JPMA President APEC Life

More information

POSTER PRESENTATIONS & POSTER DISCUSSIONS

POSTER PRESENTATIONS & POSTER DISCUSSIONS POSTER PRESENTATIONS & POSTER DISCUSSIONS Poster Presentation with Short Oral Presentation Short oral presentations are held on November 14 and 15 between 12:10-13:50. Speakers are asked to give the presentation

More information

Table of contents. Executive Summary. Chapter 1 Introduction. Chapter 2 Trends in monoclonal antibody dealmaking

Table of contents. Executive Summary. Chapter 1 Introduction. Chapter 2 Trends in monoclonal antibody dealmaking Table of contents Executive Summary Chapter 1 Introduction Chapter 2 Trends in monoclonal antibody dealmaking 2.1. Introduction 2.2. Monoclonal antibody partnering over the years 2.3. Bigpharma monoclonal

More information

MARKETS & CUSTOMERS. Progressing globalization. Evolving markets

MARKETS & CUSTOMERS. Progressing globalization. Evolving markets Peptides are used worldwide in medical research. They contribute immensely to the understanding of diseases and have proven to be effective in medicinal products. Today, peptides can be produced at low

More information

Scilab & Scilab Cloud

Scilab & Scilab Cloud Scilab & Scilab Cloud Open- source & Cloud platforms for the development & deployment of scientific & engineering applications Raphael Auphan & Yann Debray Scilab - ESI Group 2017/11/16 1 Copyright ESI

More information

Helping unlock growth opportunities worldwide

Helping unlock growth opportunities worldwide Helping unlock growth opportunities worldwide A trusted partner for high-stakes decisions While scientific and technological advances fuel new business opportunities, the cost of bringing each new product

More information

Territory Account Manager (MD, NC or TX based)

Territory Account Manager (MD, NC or TX based) Territory Account Manager (MD, NC or TX based) Looking for bilingual Chinese-English young professionals with passion in selling genomics services. The Territory Account Manager's role is to ensure achievement

More information

Organizational Capability and Competitive. Advantage in Pharmaceutical Product Development

Organizational Capability and Competitive. Advantage in Pharmaceutical Product Development Annals of Business Administrative Science Vol.2, No.2 (April 2003) Organizational Capability and Competitive Advantage in Pharmaceutical Product Development Kenichi KUWASHIMA Graduate School of Business

More information

Regenerative Medicine in Japan

Regenerative Medicine in Japan Cell & Gene Therapy World 2017 Regenerative Medicine in Japan January 19, 2017 Table of Contents Section Title Page # Japanese Regenerative Medicine Market Participants 3 Regenerative Medicine R&D in Japan

More information

Welcome to December Hotel Okura Tokyo, Japan

Welcome to December Hotel Okura Tokyo, Japan Welcome to 9 10 December 2013 Hotel Okura Tokyo, Japan What is CASSS? Non-profit professional membership society that provides networking and peer-to-peer learning opportunities for professionals involved

More information

Datamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar

Datamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar Datamonitor Healthcare 2017 Datamonitor Healthcare Content Calendar 2017 Content Calendar Published February 2017 Datamonitor Healthcare provides up-to-date insights and analysis that you can trust. Disease

More information

The Role of the European Environment Agency and EU Environmental Policies

The Role of the European Environment Agency and EU Environmental Policies 2 The Role of the European Environment Agency and EU Environmental Policies Ryukoku University, Kyoto City, Japan 13 May 2017 Stefan Speck Content European Environment Agency (EEA) who we are, what we

More information

Biotech in Japan: leveraging unexploited opportunities. Seiji Hirasaki, AnGes MG 14 March 2008 JETRO Japan Seminar at BioSquare

Biotech in Japan: leveraging unexploited opportunities. Seiji Hirasaki, AnGes MG 14 March 2008 JETRO Japan Seminar at BioSquare Biotech in Japan: leveraging unexploited opportunities Seiji Hirasaki, AnGes MG 14 March 2008 JETRO Japan Seminar at BioSquare 1 Contents 1. Japan s biotech market 2. Players: emerging biotech start-ups

More information

Technology Transfer, Academic and Industry Cooperations

Technology Transfer, Academic and Industry Cooperations Technology Transfer, Academic and Industry Cooperations Jake Micallef PhD MBA COO ValiRx plc Visiting lecturer Simfonec Jake.micallef@valirx.com What do they want? Universities Money to fund research and

More information

Regulatory Progress of 3D Printing in Taiwan

Regulatory Progress of 3D Printing in Taiwan 6th Joint Conference of Taiwan and Japan on Medical Products Regulation Regulatory Progress of 3D Printing in Taiwan Cheng-Wen Lan Senior Reviewer, Division of Medical Devices and Cosmetics 2018.10.11

More information

Human ips/es Cell Technology and Its Application to Toxicology Testing

Human ips/es Cell Technology and Its Application to Toxicology Testing Human ips/es Cell Technology and Its Application to Toxicology Testing -Especially focusing on in vitro cardiac function toxicity- Atsushi Sanbuissho, PhD Daiichi Sankyo Co., Ltd. Kenji Yasuda, Prof Tokyo

More information

Mitsubishi Pharma Corporation reaches a basic agreement to merge with Tanabe Seiyaku Co., Ltd.

Mitsubishi Pharma Corporation reaches a basic agreement to merge with Tanabe Seiyaku Co., Ltd. February 2, 2007 Mitsubishi Chemical Holdings Corporation Mitsubishi Pharma Corporation reaches a basic agreement to merge with Tanabe Seiyaku Co., Ltd. -Presentation Material- The attached document is

More information

Accelrys ROTH Growth Stock Conference

Accelrys ROTH Growth Stock Conference Accelrys ROTH Growth Stock Conference Feb. 20, 2008 Presented by: Mark Emkjer, CEO Rick Russo, CFO Forward-looking Statements When used in this presentation, words such as expects, believes, anticipates,

More information

U.S. NUCLEAR POWER PLANT DECOMMISSIONING

U.S. NUCLEAR POWER PLANT DECOMMISSIONING U.S. NUCLEAR POWER PLANT DECOMMISSIONING Workshop on Decommissioning of Nuclear Power Plants Tokyo, Japan June 30, 2017 PAUL T. DICKMAN Senior Policy Fellow, Washington DC Office Argonne National Laboratory

More information

Decisions taken in COP16 and 17: The MRV landscape

Decisions taken in COP16 and 17: The MRV landscape Session I: NC Updating and discussion on WGIA-activity Decisions taken in COP16 and 17: The MRV landscape The 10th Workshop on GHG Inventories in Asia (WGIA10) 11 July 2012 Sheraton Hanoi Hotel, Hanoi,

More information

Objective. To discuss how Japan sites can conduct Investigator Initiated Clinical Research/Trials (IITs) using unapproved drugs at an early stage

Objective. To discuss how Japan sites can conduct Investigator Initiated Clinical Research/Trials (IITs) using unapproved drugs at an early stage A Pharmaceutical Company's View on Investigator Initiated Clinical Research/Trial with Unapproved Drugs 研究者主導未承認薬臨床試験に対する企業の考え方 ファイザー株式会社クリニカルリサーチ統括部オンコロジー疾患領域部廣橋朋子 Objective To discuss how Japan sites

More information

Guide to Valuation of Pharmaceutical Licensing Deals

Guide to Valuation of Pharmaceutical Licensing Deals Guide to Valuation of Pharmaceutical Licensing Deals Edited by Taskin Ahmed and Heather Cartwright SYNDICATED ANALYTICS PHARMADEALS Contents 1 Introduction... 7 1.1 Dealmaking in the Pharmaceutical Industry...

More information

JP Morgan. Global Healthcare Conference. Robert Friel, Chairman and CEO January 11, PerkinElmer

JP Morgan. Global Healthcare Conference. Robert Friel, Chairman and CEO January 11, PerkinElmer JP Morgan Global Healthcare Conference Robert Friel, Chairman and CEO January 11, 2017 2016 PerkinElmer Factors affecting future performance & non-gaap financial measures This presentation contains "forward-looking"

More information

Three Actions for LCSs

Three Actions for LCSs Three Actions for LCSs Tokyo Institute of Technology Hiroto Takayama Kazufumi Takashina Kou Morimoto Tasuku Hasegawa Chie Tanabe Oct. 31, 2008 Narrative Scenario Annual Growth rate : Approximately 2% of

More information

Evaluate Data Kit Pharma, Biotech and Medtech, May 2018

Evaluate Data Kit Pharma, Biotech and Medtech, May 2018 Evaluate Data Kit Pharma, Biotech and Medtech, May 2018 Contents Introduction 2 Sourcing Instructions / About Evaluate 3 Section 1 Pharma Industry Overview Top 15 Rx and OTC Sales 4 WW Rx and OTC Sales

More information

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215

More information

Investigator Initiated Research and Data Usage in Japan

Investigator Initiated Research and Data Usage in Japan Investigator Initiated Research and Data Usage in Japan 2018 September 13 Kyoto University Muneo TAKATANI Origins of a Decade of New Drugs R. Kneller Nature Review Drug Discovery 9:867 (2010) 2 Novel FDA

More information

ARQULE AND DAIICHI-SANKYO ENTER INTO STRATEGIC R&D PARTNERSHIP TO PROGRESS NOVEL COMPOUNDS TO TARGET CANCER

ARQULE AND DAIICHI-SANKYO ENTER INTO STRATEGIC R&D PARTNERSHIP TO PROGRESS NOVEL COMPOUNDS TO TARGET CANCER For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

More information

An integrated model approach to improve the management of marketed products

An integrated model approach to improve the management of marketed products Insight brief Regulatory and safety integration An integrated model approach to improve the management of marketed products Leo Dodds, Principal, Quintiles Advisory Services John Rogers, Engagement Leader,

More information

Outreach in Japan. HESI Assembly of Members Annual Business Meeting May 12, Ayako Takei HESI Scientific Advisor in Japan

Outreach in Japan. HESI Assembly of Members Annual Business Meeting May 12, Ayako Takei HESI Scientific Advisor in Japan Outreach in Japan HESI Assembly of Members Annual Business Meeting May 12, 2010 Ayako Takei HESI Scientific Advisor in Japan HESI Webinar for Japan/Asia Webinar on April 13, 9 10 AM Japan time The first

More information

PRELIMINARY AGENDA ** Attendees must already be registered to attend cphi Japan conference**

PRELIMINARY AGENDA ** Attendees must already be registered to attend cphi Japan conference** PRELIMINARY AGENDA ** Attendees must already be registered to attend cphi Japan conference** The Future of Biologics Development and Manufacturing 20 April 2017 13:00 16:00 Big Sight Exhibition Center,

More information

GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)

GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS

More information

M a x i m i z in g Value from NGS Analytics in t h e E n terprise

M a x i m i z in g Value from NGS Analytics in t h e E n terprise Global Headquarters: 5 Speen Street Framingham, MA 01701 USA P.508.935.4445 F.508.988.7881 www.idc-hi.com M a x i m i z in g Value from NGS Analytics in t h e E n terprise C U S T O M I N D U S T R Y B

More information

Astellas Reports Financial Results for the First Nine Months of FY2017

Astellas Reports Financial Results for the First Nine Months of FY2017 Press Release Astellas Reports Financial Results for the First Nine Months of FY2017 Sales (-0.6%) and core operating profit (-8.8%) decreased due to the impact of certain items such as the transfer of

More information

Japan's New Growth Strategy: MSD s Contribution as a Global Company

Japan's New Growth Strategy: MSD s Contribution as a Global Company Japan's New Growth Strategy: MSD s Contribution as a Global Company Presentation at Pharma Delegates Tony Alvarez Representative Director and President MSD K.K. January 20, 2011 Forward-Looking Statement

More information

Measuring Broadband America:

Measuring Broadband America: Measuring Broadband America: Fixed and Mobile Broadband Performance Measurement Open Platforms & Opportunities for Collaboration Panel Discussion: Network Performance and Measurement Instrumenting Community

More information

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing

Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from

More information

Janssens Discovery Data Integrity program (DDI): A journey over the last 7 years Research Integrity: Position yourself for success!

Janssens Discovery Data Integrity program (DDI): A journey over the last 7 years Research Integrity: Position yourself for success! Janssens Discovery Data Integrity program (DDI): A journey over the last 7 years Research Integrity: Position yourself for success! David J. Gallacher, PhD DDI Co-Lead, Global Head of Safety Pharmacology

More information

Passion for Excellence. Commitment to Delivery.

Passion for Excellence. Commitment to Delivery. Passion for Excellence. Commitment to Delivery. Mission Statement 3 Passion for Excellence. Commitment to Delivery. Lodestone is a global management consultancy, committed to designing and delivering solutions

More information

Japan Pharma Outlook 2027 Report Extract

Japan Pharma Outlook 2027 Report Extract Datamonitor Healthcare Pharma intelligence Japan Pharma Outlook 2027 Report Extract Find out more about the full report Introduction Japan Pharma must navigate complex pressures and opportunities presented

More information

Novartis Business Services HR University Relations. Chemical and Analytical Development. Early Talent Program

Novartis Business Services HR University Relations. Chemical and Analytical Development. Early Talent Program Novartis Business Services HR University Relations Chemical and Analytical Development Early Talent Program 2 CHEMICAL AND ANALYTICAL DEVELOPMENT CHEMICAL AND ANALYTICAL DEVELOPMENT 3 Chemical and Analytical

More information

Developing Strong Partnerships to Ensure Success With Global Medical Device Trials. 23-February-2017, OCT Burlingame

Developing Strong Partnerships to Ensure Success With Global Medical Device Trials. 23-February-2017, OCT Burlingame Developing Strong Partnerships to Ensure Success With Global Medical Device Trials 23-February-2017, OCT Burlingame www.genae.com With you, for you Agenda 01 02 Identify the core group of stakeholders

More information

Investor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER

Investor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER Investor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER Forward-Looking Statement Disclaimer In order to take advantage of the safe harbor provisions of the private securities litigation reform

More information

MES Middle Ages Evolution Space. Florian Seitz Werum Asia Support Centre

MES Middle Ages Evolution Space. Florian Seitz Werum Asia Support Centre MES From Past to Present to Future 1 MES Middle Ages Evolution Space Florian Seitz Werum Asia Support Centre MES From Past to Present to Future 2 From Past to Present to Future Nokia 5100 iphone 5 15 years

More information

Policies that encourage innovation in middle-income countries

Policies that encourage innovation in middle-income countries December 2012 Policies that encourage innovation in middle-income countries The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked Charles River Associates (CRA) to

More information

Career Growth Areas in Physiology / Pharmacology

Career Growth Areas in Physiology / Pharmacology Career Growth Areas in Physiology / Pharmacology Magdalena Alonso-Galicia, PhD Pharmacology Department Forest Research Institute, Inc. Jersey City, NJ 1 Career Growth Areas in BioPharma n Pharmaceutical

More information

Japan: A practical approach and challenges for Europeans

Japan: A practical approach and challenges for Europeans Japan: A practical approach and challenges for Europeans 2014/11/19 PERSPECTIVES OF DOING BUSINESS IN JAPAN ENGINEERING SYSTEMS SOLUTION SLOVAKIA s.r.o. 1. Profiles About the speaker: Milan BUCHMAN More

More information

BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS : TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within

More information

2 Day Seminar Assuring Data Integrity in the Life Science industry. Manufacturers

2 Day Seminar Assuring Data Integrity in the Life Science industry. Manufacturers 2 Day Seminar Assuring Data Integrity in the Life Science industry Manufacturers 12 RAPS CREDITS Location 1: Apr 06 07 Boston Location 2: Apr 20 21 San Francisco, CA Seminar One Registration $ 1195 06-Apr,

More information

Collaborative Robots and Industry 4.0. A Technology Leader

Collaborative Robots and Industry 4.0. A Technology Leader Collaborative Robots and Industry 4.0 A Technology Leader Collaborative Robots and Industry 4.0 Mitsubishi 144 Years of growing into a major brand covering over 40 companies Mitsubishi Gas Chemical Mitsubishi

More information

Quintiles Transnational Corporation Big is Beautiful

Quintiles Transnational Corporation Big is Beautiful Company Overview Quintiles Transnational Corporation Big is Beautiful Quintiles Transnational is the market leader in providing a full range of integrated product development and commercial development

More information

Non Deal Roadshow - Europe

Non Deal Roadshow - Europe Non Deal Roadshow - Europe 2015 May Analyst Meeting February/March 2016 The world leader in serving science The world leader in serving science Non-GAAP Measures This presentation contains certain financial

More information

Global Competitiveness, Market Demand and the US Plastics Processing Industry

Global Competitiveness, Market Demand and the US Plastics Processing Industry Global Competitiveness, Market Demand and the US Plastics Processing Industry Platts Asian Petrochemicals Markets Conference 2016 Grand Hyatt Pudong Shanghai, China August 30-31, 2016 Presented By: Michael

More information

Application-Centric Transformation for the Digital Age

Application-Centric Transformation for the Digital Age Application-Centric Transformation for the Digital Age APRIL 2017 PREPARED FOR COPYRIGHT 2017 451 RESEARCH. ALL RIGHTS RESERVED. About this paper A Black & White paper is a study based on primary research

More information

Company Profile. German-Taiwan Biotech Seminar 6 November 2017

Company Profile. German-Taiwan Biotech Seminar 6 November 2017 Company Profile German-Taiwan Biotech Seminar 6 November 2017 Our Mission Bayer: Science For A Better Life A growing and aging world population requires an adequate supply of food and improved medical

More information

Solid and stable core business and Steady development of a growth business

Solid and stable core business and Steady development of a growth business Strategies of Takara Group p1 Strong Core, Steady Growth Solid and stable core business and Steady development of a growth business February 26, 21 Takara Holdings Inc. Representative Director, Exective

More information

Experience of Medicago working with Innovation intensive Japanese companies in the life sciences sector.

Experience of Medicago working with Innovation intensive Japanese companies in the life sciences sector. Experience of Medicago working with Innovation intensive Japanese companies in the life sciences sector. June 2013 TSX: MDG OTCQX: MDCGF www.medicago.com Forward-Looking Statements and Disclaimers This

More information

Corporate Reputation of Pharma in 2017 the Patient Perspective

Corporate Reputation of Pharma in 2017 the Patient Perspective PRESS RELEASE: 'Corporate Reputation of Pharma in - the Global Patient Perspective' Corporate Reputation of Pharma in the Patient Perspective EMBARGOED PRESS RELEASE: 6AM GMT, THURSDAY, APRIL 5TH 2018

More information

Pharma. Vision. The first single view of the risk and reward of the R&D landscape

Pharma. Vision. The first single view of the risk and reward of the R&D landscape The first single view of the risk and reward of the R&D landscape We re proud and excited to introduce the latest stage of evolution for our flagship product, EvaluatePharma. Alex Karle CEO, Evaluate Evaluate

More information

The Lessons from Indonesia

The Lessons from Indonesia The Lessons from Indonesia Dr. Brian W Tempest www.briantempest.com Brian.tempest@clara.co.uk Kuala Lumpur, Malaysia 29 th April 2010 The Lessons from Indonesia Indonesia Visit Dates March 7-12 2010 Case

More information

Updates on Tuna farming. Status on the Bluefin Tuna Seedling Production and Farming in Japan. TUNA th May 2018, Bangkok

Updates on Tuna farming. Status on the Bluefin Tuna Seedling Production and Farming in Japan. TUNA th May 2018, Bangkok TUNA 2018 30 th May 2018, Bangkok Updates on Tuna farming Status on the Bluefin Tuna Seedling Production and Farming in Japan Aquaculture Research Institute Kindai University Shukei Masuma Fig. Location

More information

JAPANESE INDUSTRY S ACTIVITIES IN BRAZIL 2018 DECEMBER 3 JAPAN EXTERNAL TRADE ORGANIZATION(JETRO) SAO PAULO OFFICE

JAPANESE INDUSTRY S ACTIVITIES IN BRAZIL 2018 DECEMBER 3 JAPAN EXTERNAL TRADE ORGANIZATION(JETRO) SAO PAULO OFFICE JAPANESE INDUSTRY S ACTIVITIES IN BRAZIL 2018 DECEMBER 3 JAPAN EXTERNAL TRADE ORGANIZATION(JETRO) SAO PAULO OFFICE Brazil s Top Import Partners (Units: US$ FOB million) 2016 2017 Value Value Shar e Growth

More information

PMDA Perspectives Yoshihiro Matsuda, Ph.D.

PMDA Perspectives Yoshihiro Matsuda, Ph.D. PMDA Perspectives Yoshihiro Matsuda, Ph.D. Office of Standards and Guidelines Development Pharmaceuticals and Medical Devices Agency (PMDA) 1 Introduction of PMDA NAME: Pharmaceuticals and Medical Devices

More information

PerkinElmer, Inc. JP Morgan Global Healthcare Conference. Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH

PerkinElmer, Inc. JP Morgan Global Healthcare Conference. Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH PerkinElmer, Inc JP Morgan Global Healthcare Conference Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH 2014 PerkinElmer FACTORS AFFECTING FUTURE PERFORMANCE & NON-GAAP

More information

Pharma/Life Sciences Hiring and Compensation Trends

Pharma/Life Sciences Hiring and Compensation Trends Pharma/Life Sciences Hiring and Compensation Trends New York Pharma Forum John McLean Managing Partner Practice Leader Global Life Sciences June 4, 2015 On the Agenda Human capital landscape Talents/skills

More information

Namiki Shoji Co., Ltd.:

Namiki Shoji Co., Ltd.: Namiki Shoji Co., Ltd.: A trading company involved in marketing pharmaceuticals, compounds for drug discovery, intermediates, and health foods; and providing various biological evaluation services of compounds.

More information

to acquire Investor And Analyst Call Presentation January 4, 2008

to acquire Investor And Analyst Call Presentation January 4, 2008 to acquire Investor And Analyst Call Presentation January 4, 2008 Safe Harbor Statement The following information contains, or may be deemed to contain, forward looking statements (as defined in the U.S.

More information

BIOTECH OUT-LICENSING OPTIMIZED COMPOUND VALUE

BIOTECH OUT-LICENSING OPTIMIZED COMPOUND VALUE 1 BIOTECH OUT-LICENSING OPTIMIZED COMPOUND VALUE Product Oriented Licensing Strategy intilaris LifeSciences Technologiepark Hochbergerstr. 60c CH-4057 Basel Switzerland Phone: +41 61 633 2212 Email: optimize@intilaris.com

More information

Strategic vision of Pharma Market

Strategic vision of Pharma Market Strategic vision of Pharma Market Evolution 2012-2016 ACIP Presentation, Paris January 30, 2013 Introduction This presentation draws strategic orientations for pharma companies considering the expected

More information

New vision for the pharmaceutical industry

New vision for the pharmaceutical industry New vision for the pharmaceutical industry Aiming at the industry with international competitive power taking the mission of innovation August 30, 2007 Ministry of Health, Labour and Welfare Table of contents

More information

Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research

Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research Transparency Market Research Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research Buy Now Request Sample Published Date: April 2014 Single User License: US

More information

Recent Developments of AEO Program in Japan

Recent Developments of AEO Program in Japan Recent Developments of AEO Program in Japan (Workshops Session 5, Track D) Hidetoshi Aramaki Customs and Tariff Bureau Ministry of Finance, Japan Outline 1. Scope of Japan s AEO Program 2. Benefits 3.

More information

On the Radar: Liaison Technologies

On the Radar: Liaison Technologies On the Radar: Liaison Technologies dpaas-based managed services for complex integration and data management requirements Publication Date: 16 Jun 2015 Product code: IT0022-000386 Saurabh Sharma Summary

More information

Open Innovation to Improve Healthcare

Open Innovation to Improve Healthcare Insérer le visuel thématique Open Innovation to Improve Creating new pharmaceutical treatments through external relationships (or Who s building the puzzle?) Insérer visuel thématique New Pharmaceutical

More information

Overview of the current Japanese biotech industry and investment outlook

Overview of the current Japanese biotech industry and investment outlook Overview of the current Japanese biotech industry and investment outlook Daiwa SMBC Capital Co.,Ltd Hiroki Narita Deputy General Manager E-mail:narita@daiwasmbc-cap.co.jp Biotechnology Market in Japan

More information

Welcome to CMC Strategy Forum Japan 2017

Welcome to CMC Strategy Forum Japan 2017 Welcome to CMC Strategy Forum Japan 2017 On behalf of the CASSS Board of Directors and the CMC Strategy Forum Global Steering Committee, we would like to extend to you a warm welcome to the second meeting

More information

Pharma. Vision. The first single view of the risk and reward of the R&D landscape

Pharma. Vision. The first single view of the risk and reward of the R&D landscape The first single view of the risk and reward of the R&D landscape We re proud and excited to introduce the latest stage of evolution for our flagship product, Evaluate. Evaluate has been at the forefront

More information

Antibody Discovery at Evotec

Antibody Discovery at Evotec Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic

More information

Real solutions for real-world problems.

Real solutions for real-world problems. Digital Health Real solutions for real-world problems. Today, it costs around $2.6 billion and takes between 10 and 15 years to develop a new drug. 1 Despite the enormity of this investment, once the drug

More information

The commercialization of biotechnology in Japan

The commercialization of biotechnology in Japan DDT Vol. 7, No. 13 July 2002 feature update The commercialization of biotechnology in Japan Christian Müller, Technical University of Hamburg-Harburg, Institute for Technology and Innovation Management,

More information

Erythropoiesis-Stimulating Agents and Beyond: A Review of the Current Landscape of Renal Anemia Research

Erythropoiesis-Stimulating Agents and Beyond: A Review of the Current Landscape of Renal Anemia Research Erythropoiesis-Stimulating Agents and Beyond: A Review of the Current Landscape of Renal Anemia Research Robin Custeau, Principal Analyst, Cardiovascular & Metabolic/Endocrinology Introduction Anemia is

More information

About DRG Consulting 1

About DRG Consulting 1 About DRG Consulting 1 DRGC Capabilities Overview Decision Resources Group (DRG) is a global information and technology services company that provides proprietary data and solutions to the healthcare industry

More information

L A B O R M A R K E T B R I E F I N G S S E R I E S

L A B O R M A R K E T B R I E F I N G S S E R I E S L A B O R M A R K E T B R I E F I N G S S E R I E S LABOR MARKET INFORMATION FOR RESEARCHERS THE LIFE SCIENCE AND PHARMACEUTICALS SECTOR IN EUROPE L I F E S C I E N C E A N D P H A R M A C E U T I C A

More information

2 nd JAPAN- INDIA MEDICAL PRODUTS REGULATION SYMPOSIUM. 24 th APRIL 2017 QUALITY STANDARDS AND GMP SYSTEM IN INDIA

2 nd JAPAN- INDIA MEDICAL PRODUTS REGULATION SYMPOSIUM. 24 th APRIL 2017 QUALITY STANDARDS AND GMP SYSTEM IN INDIA Dr V. G. SOMANI Joint Drugs Controller (India) Central Drugs Standard Control Organization DGHS, MoHFW, New Delhi v.g.somani30@cdsco.nic.in 2 nd JAPAN- INDIA MEDICAL PRODUTS REGULATION SYMPOSIUM 24 th

More information

Market Report Biopharmaceuticals and Biosimilars

Market Report Biopharmaceuticals and Biosimilars Market Report Biopharmaceuticals and Biosimilars December, 2017 **Disclaimer of Warranties** While JETRO makes every effort to ensure that we provide accurate information and advice regarding laws and

More information

Build v/s Buy Laboratory Information Management System

Build v/s Buy Laboratory Information Management System WHITE PAPER Build v/s Buy Laboratory Information Management System Table of Contents 1. Introduction 3 2. A LIMS Primer 3 3. What is a COTS Solution? 4 4. Can a Pharmaceutical LIMS Really Be a COTS? 4

More information

IEEJ: August 2012 All Right Reserved Ministry of infrastructure and energy Republic of Serbia IEEJ : June 2012 JICA TRAINING AND DIALOG PROGRAMS ENERG

IEEJ: August 2012 All Right Reserved Ministry of infrastructure and energy Republic of Serbia IEEJ : June 2012 JICA TRAINING AND DIALOG PROGRAMS ENERG Ministry of infrastructure and energy IEEJ : June 2012 JICA TRAINING AND DIALOG PROGRAMS ENERGY POLICY (B) Country Report, Jun 2012 Nominee: Vesna M. Simic, MSc. Mechanical Engineering Department for Renewable

More information

Strategic Overview of the Biotechnology Industry

Strategic Overview of the Biotechnology Industry Strategic Overview of the Biotechnology Industry Cavan Redmond Executive Vice President General Manager Wyeth BioPharma Business Unit June 15, 2004 2003Wyeth. Risk and Innovation Create Opportunity Biotech

More information

Secure Interim Analysis Data Access. Management with ACES. Eric J. Silva, Cytel, Inc. Steven Ketchum, Ph.D., Sunesis Pharmaceuticals

Secure Interim Analysis Data Access. Management with ACES. Eric J. Silva, Cytel, Inc. Steven Ketchum, Ph.D., Sunesis Pharmaceuticals Secure Interim Analysis Data Access and Automated DMC/DSMB Management with ACES Eric J. Silva, Cytel, Inc. Steven Ketchum, Ph.D., Sunesis Pharmaceuticals Introductions: Today s Speakers Eric J. Silva Manager,

More information

COUNTERFEIT PURCHASES: DELIBERATE OR NOT?

COUNTERFEIT PURCHASES: DELIBERATE OR NOT? COUNTERFEIT PURCHASES: DELIBERATE OR NOT? KGO interviews MarkMonitor brand protection expert, Akino Chikada to learn about the latest counterfeit trends. Akino Chikada, Sr. Product Marketing Manager, MarkMonitor

More information

The Geopolitics of Northeast Asia s Pipeline Development

The Geopolitics of Northeast Asia s Pipeline Development The Geopolitics of Northeast Asia s Pipeline Development Shoichi ITOH Non-resident Adjunct Fellow Center for Strategic and International Studies & Associate Senior Researcher Economic Research Institute

More information

Welcome to CMC Strategy Forum Japan 2015

Welcome to CMC Strategy Forum Japan 2015 Welcome to CMC Strategy Forum 2015 On behalf of the CASSS Board of Directors and the CMC Strategy Forum Global Steering Committee, we would like to extend to you a warm welcome to the second meeting of

More information

Dramatic Changes in the Environment for New Drug Creation and Challenges Facing Japan s Pharmaceutical Industry

Dramatic Changes in the Environment for New Drug Creation and Challenges Facing Japan s Pharmaceutical Industry Dramatic Changes in the Environment for New Drug Creation and Challenges Facing Japan s Pharmaceutical Industry Chugai Pharmaceutical Co., Ltd. Chairman & CEO Osamu Nagayama October 30, 2017 Forward-Looking

More information

PHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India)

PHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India) PHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India) COPY Date : 23-02-2010 News / Story reproduced with thanks:- Stockmarkest.com Indian pharmaceutical industry has

More information

List of contributors List of abbreviations. 1 The business of healthcare innovation in the Wharton School curriculum 1

List of contributors List of abbreviations. 1 The business of healthcare innovation in the Wharton School curriculum 1 Contents List of contributors List of abbreviations page viii xiv xvii 1 The business of healthcare innovation in the Wharton School curriculum 1 Lawton Robert Burns 2 The pharmaceutical sector: rebooted

More information

PMDA Activities for Implementation of Continuous Manufacturing

PMDA Activities for Implementation of Continuous Manufacturing PMDA Activities for Implementation of Continuous Manufacturing Yoshihiro Matsuda, Ph.D. Senior Scientist (for Quality) Pharmaceuticals and Medical Devices Agency (PMDA) 2018 ISPE CM workshop 1 Innovative

More information